Drug
Selonsertib clinical trials
Also written GS-4997.
- studies test it
- 11
- open now
- 0
- in phase 3
- 2
- first study started
- 2014
How studies write it
Studies that test it under each name
Name
- SEL
- 6
Development codes
Studies by the year they started
11 studies that test it; most in 2016 (3)
| Year | Studies |
|---|---|
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 1
- Phase 2
- 7
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 0
Gilead Sciences (10) · HepQuant, LLC (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses selonsertib is read from its arms, and is right about nine times in ten.
Testing it · 11
- Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney DiseaseCompletedPhase 2Gilead SciencesNCT04026165Written as SEL
- Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)CompletedPhase 2Gilead SciencesNCT02781584Written as SEL
- Evaluation of HepQuant SHUNT to Assess Liver Disease; Substudy Within GS-US-416-2124WithdrawnEarly Phase 1HepQuant, LLCNCT03087968Written as GS-4997
- Study to Evaluate the Pharmacokinetics of Selonsertib in Participants With Normal and Impaired Hepatic FunctionCompletedPhase 1Gilead SciencesNCT02509624Written as Selonsertib
- Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)CompletedPhase 2Gilead SciencesNCT03449446Written as SEL
- Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) FibrosisTerminatedPhase 3Gilead SciencesNCT03053050Written as SEL
- Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)TerminatedPhase 3Gilead SciencesNCT03053063Written as SEL
- Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney DiseaseCompletedPhase 2Gilead SciencesNCT02177786Written as Selonsertib
- Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3CompletedPhase 2Gilead SciencesNCT02466516Written as SEL
- Selonsertib in Adults With Pulmonary Arterial HypertensionCompletedPhase 2Gilead SciencesNCT02234141Written as Placebo
- Selonsertib in Combination With Prednisolone Versus Prednisolone Alone in Participants With Severe Alcoholic Hepatitis (AH)CompletedPhase 2Gilead SciencesNCT02854631Written as Selonsertib
Codes
What other systems call selonsertib · ClinicalTrials.gg INT001202
- MeSH (NLM) C000654501selonsertibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) NS3988A2TCSELONSERTIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27088777selonsertibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C121943SelonsertibOne source FDA
- DrugBank DB14916One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000654501 | selonsertib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | NS3988A2TC | SELONSERTIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27088777 | selonsertib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C121943 | Selonsertib | One source FDA |
| DrugBank | DB14916 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.